| scholarly article | Q13442814 |
| P356 | DOI | 10.2174/157488611798280924 |
| P698 | PubMed publication ID | 22129319 |
| P50 | author | José Alexandre de Souza Crippa | Q66605755 |
| Antonio Waldo Zuardi | Q60324489 | ||
| P2093 | author name string | Mateus Machado Bergamaschi | |
| Regina Helena Costa Queiroz | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cannabis sativa | Q26726 |
| cannabidiol | Q422917 | ||
| P304 | page(s) | 237-249 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Current Drug Safety | Q15760053 |
| P1476 | title | Safety and side effects of cannabidiol, a Cannabis sativa constituent | |
| P478 | volume | 6 |
| Q41016981 | A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans |
| Q90263162 | A Cross-Sectional Study of Cannabidiol Users |
| Q92701738 | A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects |
| Q64253834 | A Novel Standardized L. Extract and Its Constituent Cannabidiol Inhibit Human Polymorphonuclear Leukocyte Functions |
| Q58094316 | A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects |
| Q59808748 | A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans |
| Q92050525 | A Warning against the Negligent Use of Cannabidiol in Professional and Amateur Athletes |
| Q55019713 | A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products. |
| Q55427906 | An Assessment of the Genotoxicity and Subchronic Toxicity of a Supercritical Fluid Extract of the Aerial Parts of Hemp. |
| Q38598487 | An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies |
| Q66678712 | An ethnobotanical study of medicinal plants used to treat skin diseases in northern Pakistan |
| Q38267810 | An overview on development and application of an experimental platform for quantitative cardiac imaging research in rabbit models of myocardial infarction |
| Q58785789 | Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer |
| Q36785192 | Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice |
| Q58727916 | Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia |
| Q92509980 | Cannabidiol Adverse Effects and Toxicity |
| Q38967514 | Cannabidiol Exposure During Neuronal Differentiation Sensitizes Cells Against Redox-Active Neurotoxins |
| Q92210214 | Cannabidiol Induces Cell Cycle Arrest and Cell Apoptosis in Human Gastric Cancer SGC-7901 Cells |
| Q90267081 | Cannabidiol Is a Novel Modulator of Bacterial Membrane Vesicles |
| Q91962253 | Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms |
| Q97428443 | Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research |
| Q34492624 | Cannabidiol as a Potential Treatment for Anxiety Disorders |
| Q55387906 | Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders? |
| Q64911493 | Cannabidiol effects on behaviour and immune gene expression in zebrafish (Danio rerio). |
| Q50541854 | Cannabidiol enhances consolidation of explicit fear extinction in humans. |
| Q58732614 | Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor |
| Q58758655 | Cannabidiol for Treatment of Childhood Epilepsy-A Cross-Sectional Survey |
| Q57476923 | Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test |
| Q42811858 | Cannabidiol promotes browning in 3T3-L1 adipocytes |
| Q38572902 | Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors |
| Q47143965 | Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells |
| Q54967067 | Cannabidiol to Improve Mobility in People with Multiple Sclerosis. |
| Q28078534 | Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy |
| Q26823267 | Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders |
| Q40701861 | Cannabinoids for the Treatment of Movement Disorders. |
| Q38560061 | Cannabis, Cannabinoids, and Cerebral Metabolism: Potential Applications in Stroke and Disorders of the Central Nervous System |
| Q21129107 | Does Cannabidiol Protect Against Adverse Psychological Effects of THC? |
| Q90169566 | Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial |
| Q37401982 | Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report |
| Q30442731 | Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain |
| Q92506685 | Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis |
| Q42244544 | Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma |
| Q59791745 | Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression |
| Q90638345 | From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases |
| Q41560648 | Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy |
| Q36987924 | Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine |
| Q37622090 | In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease |
| Q33716706 | Interaction Between the Cannabinoid and Vanilloid Systems on Anxiety in Male Rats |
| Q33658933 | Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life |
| Q64781374 | Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms? |
| Q26865370 | Is the cardiovascular system a therapeutic target for cannabidiol? |
| Q46449901 | Labeling Accuracy of Cannabidiol Extracts Sold Online |
| Q57809211 | Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells |
| Q21090461 | Marijuana: current concepts(†) |
| Q55379948 | Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model. |
| Q93036841 | New Targeted Treatments for Fragile X Syndrome |
| Q55120181 | No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. |
| Q93023762 | Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis |
| Q37006281 | Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis |
| Q47156397 | Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. |
| Q61813934 | Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation |
| Q91721752 | Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy |
| Q91940230 | Pharmacological interventions during the process of reconsolidation of aversive memories: A systematic review |
| Q92921940 | Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission? |
| Q34557613 | Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders |
| Q46111417 | Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation |
| Q91746887 | Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use |
| Q33621686 | Potential effects of cannabidiol as a wake-promoting agent |
| Q89967869 | Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs |
| Q101127463 | Preliminary data on the potential for unintentional anti-doping rule violations by permitted CBD use |
| Q26746192 | Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review |
| Q52316000 | Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. |
| Q55439675 | Review of the neurological benefits of phytocannabinoids. |
| Q30357558 | Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation |
| Q38697025 | Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia. |
| Q89985028 | Safety Assessment of a Hemp Extract using Genotoxicity and Oral Repeat-Dose Toxicity Studies in Sprague-Dawley Rats |
| Q26798333 | Safety and Toxicology of Cannabinoids |
| Q37187618 | Screening Medications for the Treatment of Cannabis Use Disorder |
| Q48448890 | Short-term effects of cannabidiol after global hypoxia-ischemia in newborn piglets |
| Q48325031 | Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology |
| Q64229781 | The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder |
| Q97523420 | The Impact of Cannabidiol on Psychiatric and Medical Conditions |
| Q52861250 | The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis. |
| Q98165843 | The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol |
| Q38830210 | The effects of herbal medicine on epilepsy |
| Q91756670 | The heterogeneity and complexity of Cannabis extracts as antitumor agents |
| Q36890194 | Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice |
| Q42904836 | Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention |
| Q57300019 | Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age |
Search more.